Home | Site Map | Contact
You are here: Home » PBL News » 2010 News

2010 News


December 2010

FT Technology Licensed to Leading Plant Biotech Company

PBL is delighted to announce that it has entered into a major licence agreement with a leading plant biotechnology company in respect of a new technology for achieving increased seed yield . The licence grants exclusive commercial rights to develop new varieties in a selected list of agricultural crops.

The technology was developed by Dr Yiguo Hong at The University of Warwick and PBL is managing the protection and development of the intellectual property under a licence from the University.

For more information please contact Dr Jan Chojecki.

Back to top


December 2010

Targeted Drug Delivery System Licensed to Aura Biosciences

PBL is pleased to announce that it has entered into an exclusive, commercial licence with Aura Biosciences Inc, for the exploitation of a particular plant-virus as a vehicle for targeted drug delivery. The technology was developed collaboratively by JIC and Aura scientists, and will now be progressed towards clinical application by Aura.

For more information, please contact Dr Martin Stocks.

Back to top


November 2010

PBL / JIC Spin-out Procarta Biosystems Receives Major New Investment

Procarta Biosystems Ltd, which is developing a novel class of DNA-based antibiotics capable of tackling drug-resistant infections, announced today a round of equity investment totaling £730,000 with the potential to rise to £1.25 million. Procarta was established in 2007 by founders Dr Michael McArthur and Professor Mervyn Bibb of the John Innes Centre (Norwich, UK) with support of PBL, the technology transfer company of John Innes Centre.  The round was led by Morningside Venture Investments Limited and included Procarta’s current investors, Rainbow Seed Fund and Iceni Seedcorn Fund.

Please click here for a link to the full article.

Back to top


November 2010

PBL Licenses Crop Enhancement Technology to Dow AgroSciences

PBL is pleased to announce it has entered into an exclusive commercial licence agreement with Dow AgroSciences for a technology from the John Innes Centre that enhances the root systems of plants.

For more information, please click here for a link to the full article.

Back to top


October 2010

Beneforté™ : Broccoli from JIC and IFR Research is Presented to US Fresh Produce Market

The broccoli arises from the work of Professor Richard Mithen and colleagues and is exclusively licensed by PBL to Seminis Vegetable Seeds Inc. 

Please click the following links for more information:

News Release: Apio / Monsanto 16 October 2010

Reference: Traka M, Mithen R F (2009).  Glucosinolates, isothiocyanates and human health.  Phytochemistry Reviews 8 (1) 269-282

       

Back to top


July 2010

PBL Reaches 500 Technologies

PBL recently coded its 500th technology, in its 15th year of operation.  PBL assesses many more technologies than those that are taken forward to the stage of being given an internal code, so we have screened literally thousands of technologies over the years.  As well as the 27 different UK Universities and Institutes that have contributed to these 500 technologies, 15 other countries, over four continents, are represented in the technologies managed by PBL.  PBL has invested over $6 million just in the costs of patent protection on these technologies.  Obviously not all the technologies we take on succeed in reaching commercial uptake, but of the technologies we do progress to file patents on, nearly half of them do go on to generate at least some revenues.

We thank our friends in the UK and around the world for entrusting their innovations to our care and we look forward to the next 500!!

Back to top


June 2010

Royal Visit for the Model Gut

As a long time ambassador for British Industry and Innovation, HRH the Duke of York recently visited Norwich, to see first hand some of the cutting edge projects that have been established on the NRP. The Duke of York visited the Model Gut laboratory at IFR, where he was shown a demonstration of the unique DGM (Dynamic Gastric Model) by co-inventor Richard Faulks, whilst Dr Martin Stocks of PBL explained how the DGM is finding increasing utility within the food and pharmaceutical industries, leading to rapidly expanding commercial interest in the model. After visiting the Model Gut, the Duke went on to see the new BBSRC Genome Analysis Centre, and met representatives of NRP institutions and the BBSRC.

For more information, please contact Dr Martin Stocks.


Back to top


May 2010

Provexis, IFR and PBL Launch Major Collaboration in Heart Health

PBL has signed an agreement with Provexis plc and the Institute of Food Research for a substantial collaborative research and development programme.  The partners will develop plant extracts and build on related intellectual property with applications in treatment and reduction of systemic inflammation.  PBL nd Provexis have previously filed joint patents in the area, and additional background intellectual property will also be licensed by PBL to Provexis, if the first stage of the programme is successful.  Provexis discovers and develops scientifically-proven functional food, medical food and dietary supplement technologies and recently obtained approval from European Commission under Art13(5) for its Fruitflow® antithrombotic technology.

For more information, please contact Dr Martin Stocks.

Back to top


April 2010

PBL Awarded Major US Patent on Short RNA

Plant Bioscience Limited (PBL) is pleased to announce that the United States Patent Office has allowed claims in its patent application 10/806,253 for detection of short RNA molecules to identify gene silencing in mammals and mammalian cells. 

Please click here for a link to the Short RNA section on our website, or here for a link to the press release.

For licensing enquiries, please contact Dr Lars von Borcke.

All other enquiries to info@pbltechnology.com.

Back to top


April 2010

PBL Enters Crop Development Partnerships in China

PBL has entered into agreements with the Institute of Botany of the Chinese Academy of Sciences (IOB-CAS), and with the Jilin Academy of Agricultural Sciences (JAAS).  IOB-CAS has established a new Centre for Bioenergy which will develop sweet sorghum as a strategic bioenergy crop for China, while JAAS is the national centre for maize transformation and has a long track record of breeding and delivering maize and sorghum varieties for the Chinese market.  Under the agreements, IOB-CAS and JAAS will introduce new plant biotechnologies from PBL into maize and sweet sorghum, bring to field testing and ultimately develop new varieties suitable for commercial release in China. 

Dr Jan Chojecki, PBL’s MD, said “These partnerships represent an excellent mechanism for us to rapidly test in field situations the early stage discoveries emerging from public research in plant science.  This is highly complementary to our existing technology transfer activities and as well as leading to new varieties for use in China, it will enable better and earlier datasets to inform commercial uptake decisions elsewhere in the world”. 

For more information, please contact Dr Jan Chojecki.

Back to top


February 2010

Key regulator of plant root growth identified

New technology for enhancing root hair growth and nutrient uptake

In a paper published on-line this month in Nature Genetics, Keke et al demonstrate that a gene called RSL4 is the master regulator of root hair growth. Root hairs are vital for nutrient uptake from the soil and are critical to allow the roots of young seedlings penetrate the soil at germination.  

Please click here to see the full article.  For more information please contact Dr Jan Chojecki.

Back to top


January 2010

Sarum Biosciences signs licence agreement with PBL for Clostridium difficile bacteriophage endolysin technology

22 January 2010: Sarum Biosciences Limited ("Sarum") and PBL, today announced the signing of an exclusive worldwide licence agreement which enables Sarum to develop and exploit therapeutic and diagnostic applications of a bacteriophage endolysin protein for the treatment and detection of Clostridium difficile, a serious healthcare concern both within the UK and the rest of the world. 

The bacteriophage endolysin technology was developed by scientists at the Institute for Food Research in Norwich (IFR), with support from the BBSRC's Follow on Fund.

Please click here to see the full article.  For more information on Clostridium Difficile Endolysin please click here or contact Dr Martin Stocks.

Back to top


News Archive:
Latest News
2017 News
2016 News
2015 News
2014 News
2013 News
2012 News
2011 News
2010 News
2009 News
2008 News
2007 News
2006 News
2005 News
2004 News
2003 News
2002 News
2001 News
2000 News

Back to top